Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

MAY 16 2022

Liquidia Announces Presentations at the 2022 American Thoracic Society (ATS) International Conference

MORRISVILLE, N.C. , May 16, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the America Thoracic
MAY 12 2022

Liquidia Reports First Quarter 2022 Financial Results and Provides Corporate Update

-  Secured access to new capital through debt and equity transactions -  Increased utilization of Treprostinil Injection with increasing payer generic mandates -  Advanced Hatch-Waxman litigation in support of final regulatory approval of YUTREPIA™ (treprostinil) inhalation powder -  Company to

btn News